Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
- Author(s)
- Thompson, MC; Harrup, RA; Coombs, CC; Roeker, LE; Pu, JJ; Choi, MY; Barr, PM; Allan, JN; Simkovic, M; Leslie, L; Rhodes, J; Chong, EA; Kamdar, M; Skarbnik, A; Lansigan, F; McCall, B; Saja, K; Dyer, MJS; Walter, HS; Lefebure, M; Thadani-Mulero, M; Boyer, M; Biondo, J; Sail, K; Manzoor, BS; Furman, R; Bantilan, KS; Goy, A; Feldman, T; Labella, D; Schuster, SJ; Park, J; Palomba, L; Zelenetz, A; Eyre, TA; Kater, AP; Seymour, JF; Mato, AR;
- Details
- Publication Year 2022,Volume 6,Issue #15,Page 4553-4557
- Journal Title
- Blood Advances
- Publication Type
- Research article
- Keywords
- Bridged Bicyclo Compounds, Heterocyclic/therapeutic use; Humans; *Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy; Retreatment; Sulfonamides/therapeutic use
- Department(s)
- Haematology
- PubMed ID
- 35736670
- Publisher's Version
- https://doi.org/10.1182/bloodadvances.2022007812
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-04-24 06:04:41
Last Modified: 2025-04-24 06:06:07